Clinical trial
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2)…
NCT00116844 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00116844 |
|---|---|
| Title | VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies. |
| Official title | Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Infections, Herpesviridae |
| Intervention type | Drug |
| Interventions | Valaciclovir, Placebo |
| Enrollment | 73 |
| Start date | Mar 29, 2005 |
| Primary completion | Jan 10, 2006 |
| Completion | Jan 10, 2006 |
| First posted | Jul 1, 2005 |
| Last update posted | Feb 12, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: